Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings; Rogier Mous; Michael Roost Clausen; Peter Johnson; Kim M. Linton; Martine E.D. Chamuleau; David John Lewis; Anna Sureda; David Cunningham; Roberto S. Oliveri; Brian Elliott; Dena DeMarco; Ada Azaryan; Christopher Chiu; Tommy Li; Ko-Mei Chen; Tahamtan Ahmadi; Elly Lugtenburg

doi:10.1016/S0140-6736(21)00889-8

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings^*, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M. Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Ko-Mei Chen, Tahamtan Ahmadi, Elly Lugtenburg

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

185 Citations (Scopus)

Original language	English
Pages (from-to)	1157-1169
Journal	The Lancet
Volume	398
Issue number	10306
Early online date	23 Sept 2021
DOIs	https://doi.org/10.1016/S0140-6736(21)00889-8
Publication status	Published - 25 Sept 2021

Access to Document

10.1016/S0140-6736(21)00889-8

Cite this

Hutchings, M., Mous, R., Roost Clausen, M., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda, A., Cunningham, D., Oliveri, R. S., Elliott, B., DeMarco, D., Azaryan, A., Chiu, C., Li, T., Chen, K.-M., Ahmadi, T., & Lugtenburg, E. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet, 398(10306), 1157-1169. https://doi.org/10.1016/S0140-6736(21)00889-8

@article{7aaa23b5505d4619ba4054599031a777,

title = "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study",

author = "Martin Hutchings and Rogier Mous and {Roost Clausen}, Michael and Peter Johnson and Linton, {Kim M.} and Chamuleau, {Martine E.D.} and Lewis, {David John} and Anna Sureda and David Cunningham and Oliveri, {Roberto S.} and Brian Elliott and Dena DeMarco and Ada Azaryan and Christopher Chiu and Tommy Li and Ko-Mei Chen and Tahamtan Ahmadi and Elly Lugtenburg",

year = "2021",

month = sep,

day = "25",

doi = "10.1016/S0140-6736(21)00889-8",

language = "English",

volume = "398",

pages = "1157--1169",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd.",

number = "10306",

}

Hutchings, M, Mous, R, Roost Clausen, M, Johnson, P, Linton, KM, Chamuleau, MED, Lewis, DJ, Sureda, A, Cunningham, D, Oliveri, RS, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K-M, Ahmadi, T & Lugtenburg, E 2021, 'Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study', The Lancet, vol. 398, no. 10306, pp. 1157-1169. https://doi.org/10.1016/S0140-6736(21)00889-8

TY - JOUR

T1 - Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

T2 - an open-label, phase 1/2 study

AU - Hutchings, Martin

AU - Mous, Rogier

AU - Roost Clausen, Michael

AU - Johnson, Peter

AU - Linton, Kim M.

AU - Chamuleau, Martine E.D.

AU - Lewis, David John

AU - Sureda, Anna

AU - Cunningham, David

AU - Oliveri, Roberto S.

AU - Elliott, Brian

AU - DeMarco, Dena

AU - Azaryan, Ada

AU - Chiu, Christopher

AU - Li, Tommy

AU - Chen, Ko-Mei

AU - Ahmadi, Tahamtan

AU - Lugtenburg, Elly

PY - 2021/9/25

Y1 - 2021/9/25

U2 - 10.1016/S0140-6736(21)00889-8

DO - 10.1016/S0140-6736(21)00889-8

M3 - Article

C2 - 34508654

SN - 0140-6736

VL - 398

SP - 1157

EP - 1169

JO - The Lancet

JF - The Lancet

IS - 10306

ER -